Unicycive Therapeutics, Inc. (UNCY)
5.16
-0.14
(-2.64%)
USD |
NASDAQ |
Sep 04, 16:00
5.155
0.00 (0.00%)
After-Hours: 20:00
Unicycive Therapeutics Research and Development Expense (Quarterly) : 2.788M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.788M |
| March 31, 2026 | 1.607M |
| December 31, 2025 | 2.25M |
| September 30, 2025 | 2.964M |
| June 30, 2025 | 1.75M |
| March 31, 2025 | 2.171M |
| December 31, 2024 | 5.288M |
| September 30, 2024 | 3.045M |
| June 30, 2024 | 4.868M |
| March 31, 2024 | 6.813M |
| December 31, 2023 | 4.233M |
| September 30, 2023 | 3.372M |
| June 30, 2023 | 2.267M |
| March 31, 2023 | 3.03M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.84M |
| September 30, 2022 | 4.803M |
| June 30, 2022 | 1.86M |
| March 31, 2022 | 1.933M |
| December 31, 2021 | 1.361M |
| September 30, 2021 | 3.776M |
| June 30, 2021 | 0.493M |
| March 31, 2021 | 0.45M |
| December 31, 2020 | 0.382M |
| September 30, 2020 | 0.304M |
| June 30, 2020 | 0.181M |
| March 31, 2020 | 0.148M |
| December 31, 2019 | 0.376M |
| September 30, 2019 | 0.188M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Theriva Biologics, Inc. | 1.268M |
| AbbVie, Inc. | 2.344B |
| Decoy Therapeutics, Inc. | 1.304M |
| Yarrow Bioscience, Inc. | 0.788M |